

Supplement Table 1. Stratified risk estimates and 95% confidence intervals for the joint effects and interaction indexes between HBV and smoking

	HBV-/Tob-	HBV-/Tob+	HBV+/Tob [*]	HBV+/Tob+	Interaction Index	
					Additive	Multiplicative
Case-control studies (N=5)						
No. of cases	112	307	124	317	860	860
Random effect	1.00	2.20 (1.72-2.80)	22.2 (9.7-50.6)	24.4 (15.9-37.4)	1.26 (0.65-2.45)	0.71 (0.39-1.27)
p for heterogeneity		0.727	0.038	0.328	0.121	0.059
Egger's test for publication bias					0.096	0.230
Cohort studies (N=4)						
No. of cases	160	653	295	1400	2508	2486
Random effect		1.50 (0.86-2.59)	11.6 (5.09-26.6)	18.1 (9.18-35.6)	1.54 (0.92-2.59)	1.07 (0.55-2.10)
p for heterogeneity		0.039	0.018	0.013	0.043	0.001
Egger's test for publication bias					0.314	0.782
Studies for Asia (N=6)						
No. of cases	170	695	360	1552	2777	2755
Random effect	1.00	1.62 (1.04-2.52)	15.8 (8.13-30.7)	22.5 (13.4-37.9)	1.53 (0.94-2.50)	0.99 (0.57-1.70)
p for heterogeneity		0.052	0.014	0.020	0.013	0.001
Egger's test for publication bias					0.520	0.480
Studies for Greece and US (N=3)						
No. of cases	102	265	59	128	554	554
Random effect		2.21 (1.71-2.85)	17.1 (6.22-47.2)	19.3 (12.4-30.1)	1.30 (0.69-2.45)	0.69 (0.42-1.15)
p for heterogeneity		0.422	0.083	0.451	0.591	0.242
Egger's test for publication bias					0.559	0.418
Studies based on incident or prevalent data (N=7)						
No. of cases	129	339	159	370	997	975
Random effect	1.00	2.26 (1.80-2.83)	19.9 (10.7-37.1)	24.2 (17.3-33.9)	1.44 (0.78-2.64)	0.67 (0.43-1.06)
p for heterogeneity		0.854	0.070	0.500	0.021	0.047
Egger's test for publication bias					0.707	0.326
Studies based mortality data (N=2)						
No. of cases	143	621	260	1310	2334	2334
Random effect	1.00	1.10 (0.92-1.32)	7.84 (1.37-45.0)	12.5 (3.28-47.3)	1.36 (1.18-1.56)	1.50 (0.76-2.97)
p for heterogeneity		0.465	0.005	0.002	0.427	0.119

Supplement Table 2. Stratified risk estimates and 95% confidence intervals for the joint effects and interaction indexes between HCV and smoking

	HCV-/Tob-	HCV-/Tob+	HCV+/Tob-	HCV+/Tob+	Interaction Index	
					Additive	Multiplicative
Case-Control Studies (N=4)						
No. of cases	156	318	49	179	702	702
Random effect	1.00	1.63 (1.32-2.00)	8.43 (5.20-13.7)	25.7 (12.0-55.4)	3.17 (1.86-5.42)	1.68 (1.16-2.41)
p for heterogeneity		0.881	0.348	0.006	0.677	0.431
Egger's test for publication bias					0.960	0.655
Cohort studies (N=2)						
No. of cases	41	55	13	21	130	130
Random effect	1.00	1.16 (0.63-2.13)	8.31 (0.89-78.0)	20.8 (0.78-552)	3.45 (1.81-6.58)	1.38 (0.72-2.63)
p for heterogeneity		0.291	0.013	<0.001	0.304	0.986
HBV prevalent countries (Taiwan and Greece) (N=3)						
No. of cases	97	221	23	78	419	419
Random effect	1.00	1.34 (1.04-1.71)	4.86 (2.79-8.44)	9.87 (4.94-19.7)	1.92 (0.84-4.40)	1.31 (0.84-2.03)
p for heterogeneity		0.353	0.376	0.002	0.964	0.970
Egger's test for publication bias					0.820	0.633
HBV low-prevalent countries (US and Japan) (N=3)						
No. of cases	100	152	39	122	413	413
Random effect	1.00	1.73 (1.31-2.28)	13.5 (5.94-30.5)	68.1 (21.4-216)	3.91 (2.48-6.17)	1.98 (1.25-3.12)
p for heterogeneity		0.731	0.168	<0.001	0.822	0.516
Egger's test for publication bias					0.396	0.819
Studies for Asia (N=4)						
No. of cases	87	96	17	40	240	240
Random effect	1.00	1.37 (1.02-1.85)	6.59 (3.09-14.0)	18.2 (5.92-56.2)	3.47 (2.20-5.46)	1.61 (1.07-2.40)
p for heterogeneity		0.326	0.409	0.381	0.779	0.950
Egger's test for publication bias					0.293	0.721
Studies for Greece and US (N=2)						
No. of cases	110	277	45	24	592	592
Random effect	1.00	1.65 (1.28-2.14)	11.4 (4.32-29.9)	38.1 (5.29-275)	3.00 (1.10-8.19)	1.87 (0.71-4.96)
p for heterogeneity		0.958	0.158	0.001	0.239	0.102